In alignment with the cellular viability assays, the combination treatment led to an enhanced fraction of annexin V‐positive cells in U87, T98G, LN229, MeWo, and HCT116 cells as well as in GBM stem‐like cells (Fig 2A and B). This evidence concerns the gene ANXA5 and glioblastoma.